Clinical Outcomes With Bioabsorbable Polymer- Versus Durable Polymer-Based Drug-Eluting and Bare-Metal Stents

Palmerini, Tullio; Biondi‐Zoccai, Giuseppe; Riva, Diego Della; Mariani, Andrea; Sabaté, Manel; Smits, Pieter C.; Kaiser, Christoph; D’Ascenzo, Fabrizio; Frati, Giacomo; Mancone, Massimo; Généreux, Philippe; Stone, Gregg W.

doi:10.1016/j.jacc.2013.09.061

Cited by 279 publications

(176 citation statements)

References 26 publications

Supporting

Mentioning

170

Contrasting

Unclassified

Order By: Relevance

“…Notwithstanding, there remains residual uncertainty whether the 2 devices differ with respect to individual safety and efficacy outcomes, notably the risk of stent thrombosis (ST). Although several network meta-analyses compared different DES, [6][7][8][9] there was an inconsistency between direct and indirect evidence with regard to the effectiveness of R-ZES and EES. 8 Therefore, we sought to perform a pairwise meta-analysis of randomized clinical trials with direct comparisons of FDAapproved new-generation DES to evaluate the safety and efficacy of R-ZES and EES in patients undergoing PCI.…”

mentioning

confidence: 99%

Safety and Efficacy of Resolute Zotarolimus-Eluting Stents Compared With Everolimus-Eluting Stents

Piccolo

Stefanini

Franzone

et al. 2015

Circ: Cardiovascular Interventions

View full text Add to dashboard Cite

Background-Although new-generation drug-eluting stents represent the standard of care among patients undergoing percutaneous coronary intervention, there remains debate about differences in efficacy and the risk of stent thrombosis between the Resolute zotarolimus-eluting stent (R-ZES) and the everolimus-eluting stent (EES). The aim of this study was to evaluate the safety and efficacy of the R-ZES compared with EES in patients undergoing percutaneous coronary intervention. Methods and Results-A systematic literature search of electronic resources was performed using specific search terms until September 2014. Random-effects meta-analysis was performed comparing clinical outcomes between patients treated with R-ZES and EES up to maximum available follow-up. The primary efficacy end point was targetvessel revascularization.

show abstract

mentioning

confidence: 99%

Safety and Efficacy of Resolute Zotarolimus-Eluting Stents Compared With Everolimus-Eluting Stents

Piccolo

Stefanini

Franzone

et al. 2015

Circ: Cardiovascular Interventions

View full text Add to dashboard Cite

show abstract

“…The optimisation of vascular response and clinical outcome of DES technologies is dependent upon multiple factors. The utilisation of biodegradable and biocompatible polymers has shown theoretical advantages in vitro and in the experimental setting [12]; however, the clinical benefit, especially when compared with second-generation durable polymer counterparts, is inconclusive [13). It seems that the type of drug, and specifically modification of the release profile, plays more pronounced role.…”

Section: Discussionmentioning

confidence: 99%

Dose-dependent vascular response following delivery of sirolimus via fast releasing, biodegradable polymer stent matrix: an experimental study in the porcine coronary model of restenosis

et al. 2015

View full text Add to dashboard Cite

A b s t r a c tBackground: Fast releasing, rapamycin-eluting stents, although safe, showed inferior results with regard to inhibition of restenosis.Aim: Therefore, we report vascular effects of a novel, biodegradable polymer stent matrix with elevated sirolimus dose and fast release kinetics (ed-frSES, Alex, Balton) in the porcine coronary in-stent restenosis model. Methods:A total of 19 stents were implanted with 120% overstretch in the coronary arteries of seven domestic pigs: seven ed-frSES with 1.3 μg/mm 2 of sirolimus, eight frSES with 1 μg/mm 2 of sirolimus, and eight bare metal stents (BMS). For the following 28 days, coronary angiography was performed, animals were sacrificed, and the stented segments harvested for histopathological evaluation. Results:In angiography at 28 days the late lumen loss was lowest in the elevated dose sirolimus eluting stent (SES) (ed-frSES: 0.20 ± 0.2 vs. frSES: 0.80 ± 0.5 vs. BMS: 0.96 ± 0.5 mm, p < 0.01). This was confirmed in the morphometric evaluation in histopathology as represented by a significant and dose-dependent decrease in the percentage area of stenosis (ed-frSES: 22.4 ± 12.7% vs. frSES: 35 ± 10.7% vs. BMS: 47.5 ± 12.5%, p < 0.01). There was no peri-strut inflammation in any of the groups. However, the endothelialisation score was numerically not meaningfully decreased in ed-frSES (ed-frSES: 2.93 vs. frSES: 3. vs. BMS: 3, p = 0.05). Signs of fibrin were also noted in ed-frSES (ed-frSES: 0.4 vs. frSES: 0 vs. BMS: 0, p = 0.05). Conclusions:Sirolimus dose-dependent vascular response was reported. The elevated dose, fast releasing SES shows satisfactory vascular healing, similar to regular dose, fast release SES, with improved efficacy in restenosis inhibition.

show abstract

“…Так, в недавно опубликованном метаанализе показано, что стенты с биодеградируемым покрытием демонстрируют результаты не хуже, а иногда и лучше предшествен-ников [27]. Дальнейшим шагом стало производство полностью биорастворимых сосудистых каркасов [28].…”

Section: стенты третьего и четвертого поколенияunclassified

A modern generation of drug-eluting stents. Focusing on a sirolimus-eluting stent Calypso

Кудряшов¹,

Требушат²,

Верин³

et al. 2017

PKiK

View full text Add to dashboard Cite

The review deals with the evolution of interventional coronary procedures and development of the state-of-art coronary stent market. Emphasis in the review is placed on comprehensive analysis of technical characteristics of the world’s most popular coronary stents versus a Russian bioresorbable sirolimus-eluting stent “Calipso”.Received 13 January 2017. Accepted 17 March 2017.Conflict of interest: Kudryashov A.N., Trebushat D.V. are “Angioline” Company employees, the producer of “Kalipso” coronary stent. Kretov E.I. served as executive editor of “Endovascular surgery” section. All other authors declare no conflict of interest.

show abstract

Clinical Outcomes With Bioabsorbable Polymer- Versus Durable Polymer-Based Drug-Eluting and Bare-Metal Stents

Abstract: In this large-scale network meta-analysis, BP-BES were associated with superior clinical outcomes compared with BMS and first-generation DES and similar rates of cardiac death/MI, MI, and TVR compared with second-generation DP-DES but higher rates of definite ST than CoCr-EES.

Cited by 279 publications

References 26 publications

Safety and Efficacy of Resolute Zotarolimus-Eluting Stents Compared With Everolimus-Eluting Stents

Safety and Efficacy of Resolute Zotarolimus-Eluting Stents Compared With Everolimus-Eluting Stents

Dose-dependent vascular response following delivery of sirolimus via fast releasing, biodegradable polymer stent matrix: an experimental study in the porcine coronary model of restenosis

A modern generation of drug-eluting stents. Focusing on a sirolimus-eluting stent Calypso

Contact Info

Product

Resources

About